ABIONYX's Half-Yearly Review of the Liquidity Contract

ABIONYX Pharma has published its half-year report concerning the liquidity contract established with TP ICAP (Europe) SA. As of June 30, 2026, the liquidity account comprised 118,866 shares and a cash balance of €96,894.38. During the first half of 2026, 282,460 shares were purchased for €933,897.51, and 226,618 shares were sold for €782,823.64, resulting in 361 and 283 transactions, respectively.

At the end of the previous year, on December 31, 2025, the account showed 63,024 shares and a balance of €257,777.69. Initially, when the contract was established, 131,000 shares and €40,801.20 in cash were available. This statement highlights the significant trading activity and liquidity surrounding ABIONYX Pharma shares.